Ratings by William Blair (Lachlan Hanbury-Brown)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/20/2026 | Surrozen Inc. | SRZN | New Coverage | Outperform (N/A) |
24.01 (22.76) |
-5.21% | Details | |
| 6/29/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/21/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2026 | Apellis Pharmaceuticals | APLS | Downgrade | Market Perform (Outperform) |
17.09 (41.03) |
140.08% | Details | |
| 3/27/2026 | ARS Pharmaceuticals Inc | SPRY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Tarsus Pharmaceuticals | TARS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Outperform (N/A) |
7.10 (8.40) |
18.31% | Details | |
| 3/17/2026 | Kalaris | KLRS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | LENZ Therapeutics Inc | LENZ | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Kalaris | KLRS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2026 | Harrow Health | HROW | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2025 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2025 | Viridian Therapeutic | VRDN | New Coverage | Outperform (N/A) |
30.43 (22.92) |
-24.68% | Details | |
| 7/10/2025 | Kalaris | KLRS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/10/2025 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Outperform (N/A) |
|
Details | ||
| 7/1/2025 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2025 | Harrow Health | HROW | New Coverage | Outperform (N/A) |
30.15 (38.54) |
27.83% | Details | |
| 4/8/2025 | Ocular Therapeutix | OCUL | New Coverage | Outperform (N/A) |
6.30 (10.64) |
68.89% | Details | |
| 4/8/2025 | Kalaris | KLRS | New Coverage | Outperform (N/A) |
6.60 (3.90) |
-40.91% | Details | |
| 10/16/2024 | Apellis Pharmaceuticals | APLS | New Coverage | Outperform (N/A) |
27.95 (17.09) |
-38.86% | Details |
